Johnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s consumer health unit. More: Johnson & Johnson drops out of the race for Pfizer consumer unit,
read moreBiogen CEO Michel Vounatsos doesn’t “see a frenzy” of M&A coming to pharma because of an influx of overseas cash. But what activity he does predict? He expects to be part of it. More: Biogen's in the hunt for late-stage
read moreDespite its struggles in 2017, Celgene turned in 16% sales growth for the year, buoyed by key drugs Revlimid, Pomalyst and Otezla. And some recent M&A could keep the growth coming. More: On heels of Juno deal, Celgene reports volume-driven
read moreIntent to focus on the first-ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets. More: Spark, Novartis tie up in gene therapy licensing deal worth up to 0M Source: fierce
read moreSome Allergan investors have felt queasy about the potential for Botox knockoffs to suck up some of the company’s bottom line. But manufacturing issues for one of those players, Evolus, could delay approval of its candidate. More: Evolus says its
read moreNovartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million. More: Novartis buys access to Spark’s vision loss therapy Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals